Abbott upgraded to Buy at Jefferies despite underwhelming outlook

2 hours ago 1

Healthcare

Wall Street New York stock exchange stock market

Abbott Laboratories (NYSE:ABT) was upgraded to Buy from Hold at Jefferies following its Q2 results and revised guidance, as analysts view the market reaction as “overly punitive” and see an attractive entry point amid transitory headwinds.

The company posted $11.1B

Recommended For You

More Trending News

Read Entire Article

Abbott upgraded to Buy at Jefferies despite underwhelming outlook

Recommended For You

More Trending News

Related

Trump set to sign landmark crypto bill as critics warn of hu...

Wall Street and SA analysts weigh in on Netflix's Q2 report

Bullish or Bearish? SA analysts weigh in on what's next for ...

Cohen & Steers outlines 7-8% G&A increase in 2025 guidance a...

Ally narrows 2025 auto net charge-off guidance to 2%–2.15% a...

U.S. makes serious progress on crypto legislation – here's w...

Amprius Technologies has doubled in six weeks amid the heigh...

PICTON Multi-Strategy Alpha Alternative Fund ETF declares CA...

Donegal Group declares $0.165 dividend

ESPN8: The Ocho is coming back – with Soap Hockey, Mailboat ...

Popular crypto site Pump.fun raised $600 million in 12 minut...

Northern Dynasty sinks again as Alaska mine settlement hopes...

Stark Tank’s Kevin O’Leary warns Gen Z that this popular cor...

Invesco stock surges after filing to convert QQQ

Autoliv outlines 3% organic sales growth and raises Q3 divid...

Verizon, AT&T Q2 Preview: Subscribers growth, capex in focus...

New Gold Coins Norms Coming Soon: Only BIS-approved mints al...

CareDx rebounds as draft LCD suggests no change in coverage

Like Mark Cuban and Barack Obama, this CEO says work-life ba...

Amphenol appears on Evercore's 'Tactical Outperform' list ah...

Trending

Popular

سفیر جدید برزیل استوارنامه خود را تقدیم عراقچی کرد

توانمند سازی صنایع و کارخانجات استان با بهره‌گیری از محصولات...